Company: BLLN
Filing Date: 2025-10-17
Form Type: S-1/A
Source: 0001193125-25-242632
Chunk: 289

Company: BillionToOne, Inc.
Filing Date: 2025-10-17
Form: S-1/A
Chunk 289
---
 with Hummingbird Ventures that purchased shares of Series C redeemable convertible preferred stock include: (i) Hummingbird Dragons CommV, and (ii) Hummingbird Opportunity Fund II CommV. 
 Firat Ileri, a member of our Board of Directors, is the managing partner of Hummingbird Ventures.                                                                                                              |

| (3) |     | Entities affiliated with Libertus Capital that purchase shares of Series C redeemable convertible preferred stock include: (i) Libertus Capital I and (ii) Libertus Capital II. Libertus Capital holds greater 
 than 5% of our capital stock.                                                                                                                                                                                  |

| (4) |     | Entities affiliated with Neotribe Ventures that purchased shares of our Series C redeemable convertible preferred stock include Neotribe SPV I BTO, LLC. Krishna Swaroop Kolluri, a member of our Board of Directors, is a 
 managing director at Neotribe Ventures.                                                                                                                                                                                    |

Secondary sales Pursuant to our 2018 Plan and the ROFR (as defined below), which is described below, certain holders of our capital stock and we or our assignees have a right of first refusal to purchase shares of our capital stock proposed to be sold by certain of our stockholders to other parties. These rights will terminate upon completion of this offering. We waived or allowed to expire our right of first refusal in connection with the following transactions involving directors, officers and holders of more than 5% of our capital stock: 215

In April 2022, Dr. Tsao entered into stock purchase agreements with us and certain affiliates of Libertus
Capital, which holds more than 5% of our capital stock. Pursuant to these agreements, Dr. Tsao sold an aggregate of 196,126 shares of common stock for aggregate cash proceeds of $4,999,977.43 at a price per share of $25.4937.

In April 2022, Dr. Atay entered into stock purchase agreements with us and certain affiliates of Libertus Capital. Pursuant to these agreements, Dr. Atay sold
an aggregate of 196,126 shares of our common stock for $4,999,977.41 aggregate cash proceeds at a price of $25.4937 per share.

In November 2022, entities affiliated
with Libertus Capital, which holds more than 5% of our capital stock, purchased an aggregate of 87,700 shares of our common stock for $1,788,